Penumbra addresses limitations of ACS management strategy

26 Jan 2024
healthcare-digital.com
Executive Change
Penumbra addresses limitations of ACS management strategy
Preview
Source: Healthcare Digital
The Indigo System CAT RX
Penumbra’s Indigo System CAT RX allows healthcare professionals to remove blood clots from the coronary & peripheral vasculature
Global healthcare company Penumbra, headquartered in California, US, is the largest company working to comprehensively address blood clots.
Founded in 2004, the company supports over 50 million people with products available in over 100 markets worldwide.
As part of its mission to make a profound impact on the high-risk coronary patient population and address the limitations of traditional management strategies for acute coronary syndrome (ACS), Penumbra has recently secured a CE Mark for its Indigo System CAT RX.
The catheter allows healthcare professionals to remove blood clots from the coronary and peripheral vasculature while maintaining sustained mechanical aspiration with support from the Penumbra ENGINE.
“Expanding access of CAT RX in Europe will have a significant impact on the high-risk coronary patient population,” says Joan Kristensen, vice president and head of the Europe, Middle East and Africa region for Penumbra, Inc.
Kristensen began her career as a nurse in Denmark, going on to spend nearly 14 years at Medtronic before she joined Penumbra in 2021.
“In what is often a race against time, CAT RX designed for speed, safety and simplicity will allow physicians to restore blood flow in acute MI patients.”
Innovative healthcare to address blood clots
“The CHEETAH findings suggest that continuous aspiration with CAT RX should be a key consideration when high thrombus burden plaque is encountered given that removing the thrombus improves perfusion,” shares James F. Benenati, Chief Medical Officer at Penumbra.
As a board-certified interventional radiologist, Benenati’s areas of interest and expertise include acute and chronic peripheral arterial and venous disease, and management of pulmonary embolism. Before joining Penumbra in 2020, he practised interventional radiology at the Miami Cardiac & Vascular Institute at Baptist Hospital for 31 years, including serving as medical director of the noninvasive vascular laboratory and fellowship program director. He is a clinical professor of radiology at the Florida International University Herbert Wertheim College of Medicine and a Collaborative Professor of Radiology at the University of South Florida Morsani College of Medicine, and he has authored over 150 scientific publications and book chapters and has lectured globally.
“CAT RX has demonstrated a high degree of safety while maximising effectiveness in removing thrombus. We believe this can lead to better outcomes for the patient.”
**************
Make sure you check out the latest industry news and insights at Healthcare Digital and also sign up to our global conference series - Tech & AI LIVE 2024
**************
Healthcare Digital is a BizClik brand
*************
Global healthcare company Penumbra, headquartered in California, US, is the largest company working to comprehensively address blood clots.
Founded in 2004, the company supports over 50 million people with products available in over 100 markets worldwide.
As part of its mission to make a profound impact on the high-risk coronary patient population and address the limitations of traditional management strategies for acute coronary syndrome (ACS), Penumbra has recently secured a CE Mark for its Indigo System CAT RX.
The catheter allows healthcare professionals to remove blood clots from the coronary and peripheral vasculature while maintaining sustained mechanical aspiration with support from the Penumbra ENGINE.
“Expanding access of CAT RX in Europe will have a significant impact on the high-risk coronary patient population,” says Joan Kristensen, vice president and head of the Europe, Middle East and Africa region for Penumbra, Inc.
Kristensen began her career as a nurse in Denmark, going on to spend nearly 14 years at Medtronic before she joined Penumbra in 2021.
“In what is often a race against time, CAT RX designed for speed, safety and simplicity will allow physicians to restore blood flow in acute MI patients.”
Innovative healthcare to address blood clots
“The CHEETAH findings suggest that continuous aspiration with CAT RX should be a key consideration when high thrombus burden plaque is encountered given that removing the thrombus improves perfusion,” shares James F. Benenati, Chief Medical Officer at Penumbra.
As a board-certified interventional radiologist, Benenati’s areas of interest and expertise include acute and chronic peripheral arterial and venous disease, and management of pulmonary embolism. Before joining Penumbra in 2020, he practised interventional radiology at the Miami Cardiac & Vascular Institute at Baptist Hospital for 31 years, including serving as medical director of the noninvasive vascular laboratory and fellowship program director. He is a clinical professor of radiology at the Florida International University Herbert Wertheim College of Medicine and a Collaborative Professor of Radiology at the University of South Florida Morsani College of Medicine, and he has authored over 150 scientific publications and book chapters and has lectured globally.
“CAT RX has demonstrated a high degree of safety while maximising effectiveness in removing thrombus. We believe this can lead to better outcomes for the patient.”
**************
Make sure you check out the latest industry news and insights at Healthcare Digital and also sign up to our global conference series - Tech & AI LIVE 2024
**************
Healthcare Digital is a BizClik brand
*************
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.